Pharmion Submits Skin Cancer Drug for Approval
Posted on: Tuesday, 23 January 2007, 12:00 CST
Pharmion Corporation has submitted a marketing authorization application with the European Medicines Agency for Thalidomide Pharmion for the treatment of skin cancer.
The marketing application is for the use of Thalidomide Pharmion in untreated multiple myeloma patients. Thalidomide Pharmion has been designated as an orphan medicinal product in the EU.
The application is based upon a clinical data package comprised of four studies. In one of the studies there was an unprecedented 21-month survival advantage demonstrated for the Thalidomide arm. Pharmion believes Thalidomide, melphalan and prednisone should rapidly become the reference therapy for this patient population.
"Our data demonstrate significant benefit when Thalidomide is added to today's standard of care in untreated elderly patients with multiple myeloma," said Philippe Moreau, professor of Clinical Hematology at Nantes Faculty of Medicine.
The company is seeking approval for Thalidomide Pharmion in combination with melphalan and prednisone for patients with untreated multiple myeloma aged 65 years or older or ineligible for high dose chemotherapy.
Pharmion is also seeking approval for Thalidomide Pharmion in combination with dexamethasone for induction therapy prior to high dose chemotherapy and bone marrow transplant, for patients with untreated multiple myeloma.
Source: Datamonitor
Related Articles
- New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer
- The International Myeloma Foundation Applauds Expansion of VELCADE(R) for Previously Untreated Patients in Europe and Canada
- The Multiple Myeloma Research Consortium (MMRC) Announces Initiation of First Four-Drug Combination Study to Treat Newly Diagnosed Multiple Myeloma Patients
- Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-Line Multiple Myeloma From European Medicines Agency
- VELCADE(R) (Bortezomib) for Injection Based Therapies Achieved Survival Rates As High As 100 Percent in Newly Diagnosed Multiple Myeloma Patients
- VELCADE(R) (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates As High As 54 Percent in Patients With Previously Treated Multiple Myeloma
- EMEA Accepts for Review Thalidomide Pharmion(R) Marketing Authorization Application for Untreated Multiple Myeloma
- Pharmion Submits Multiple Myeloma Drug for Approval
- Pharmion Submits European Marketing Authorization Application for Thalidomide Pharmion(R) for Untreated Multiple Myeloma
- Depression Often Untreated in Heart Patients
 |
 |
User Comments (0)
RSS Feeds